Sebastijan Hobor

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

A. Bardelli, M. Buscarino, F. Di Nicolantonio, 2014, Science Translational Medicine.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Beatriz Bellosillo, Enzo Medico, Giuseppe Rospo, 2015, Nature Medicine.

Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal

Zoltan Szallasi, Ashish Chandra, Adam Huffman, 2018, Cell.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Andreas Schlicker, Anirudh Prahallad, Andrea Bertotti, 2014, Cell reports.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Andrea Bertotti, Simona Corso, Maria Apicella, 2013, Cancer discovery.